Boundless Bio Inc.

Animal Exploitation (Testing): Yes Link: S-1 – SEC.gov Short Description: Boundless Bio is a clinical-stage oncology (cancer) biopharmaceutical company developing new drug candidates (ecDNA-directed therapies – ecDTx). As is standard for drug development in the preclinical stage, the company uses animal models (likely mice, given the industry and common practice) for testing drug efficacy and safety before human clinical trials. The SEC filing mentions preclinical models. Exact Quote from Link: “Our lead ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is currently being studied in a first-in-human, Phase 1/2 clinical trial in patients with oncogene amplified cancers.” (The use of “preclinical cancer models” in oncology drug development refers to animal testing, primarily on mice/rodents, to demonstrate a compound’s effect on tumors.)